Trial Search Results
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer
Stanford is currently not accepting patients for this trial.
- Drug: AZD4877
- Confirmed urothelial cancer (cancer of the bladder, renal pelvis, ureter, or urethra).
- Tumor, Node, Metastasis (TNM) Stage IV urothelial cancer that can not be helped by
curative surgery and/or curative radiotherapy
- Must have had a maximum of 2 prior chemotherapeutic regimens, one for unremovable
and/or metastasized disease, and the other in the adjuvant or neo-adjuvant setting.
- Ambulatory and capable of all selfcare more than 50% of waking hours
- Prior treatment with investigational or standard anti-cancer agents, including
radiotherapy, within 4 weeks prior to first dose of study medication; 6 weeks if prior
systemic mitomycin, nitrosourea, or suramin.
- Inadequate bone marrow reserve
- Inadequate liver function in the presence of liver metastases
- Impaired renal function
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study